Exact Sciences, colorectal cancer
Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a small study.
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial
The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting algorithm.
Exact Sciences says data support its colon cancer blood test
Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.
Exact Sciences spikes ahead of data for blood-based cancer test
Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more here.
ESMO: Exact Sciences shows off early colorectal cancer blood test data
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors | Presented at the annual meeting of the European Society for Medical Oncology,
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.
STAT7d
The essential biotech updates of the day
AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...
Exact Sciences Unusual Options Activity For September 16
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...
FiercePharma7d
Exact Sciences debuts first Spanish-language Cologuard ads to drive colon cancer screening in Latino community
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign ...
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential
Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...
Should You Hold Exact Sciences Corporation (EXAS)?
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor ...
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Mizuho boosted American Tower Corporation AMT price target from $205 to $221. Mizuho analyst Vikram Malhorta maintained a ...
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
STAT4d
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...